FDA Grants Priority Review to Darzalex Combo Therapy for Relapsed Multiple Myeloma Patients

The U.S. Food and Drug Administration (FDA) is giving priority review to a supplemental Biologics License Application (sBLA) to approve Genmab‘s Darzalex (…